Firefly Neuroscience (AIFF)
NASDAQ:AIFF
Top Page
Firefly Neuroscience
(NASDAQ:AIFF)
Select Model
Select Model
Rating:53Neutral
Price Target:
$2.50
▲(138.10% Upside)
Action:ReiteratedDate:04/02/26
The score is held back primarily by weak financial performance—large losses and significant cash burn despite improved revenue and a healthier, debt-free balance sheet. Technicals are supportive with price above key moving averages and positive MACD, while recent financing events modestly help liquidity but introduce dilution risk; valuation support is limited due to unusable/absent standard metrics.
Positive Factors
FDA-cleared Evoke platform
FDA 510(k) clearance gives the Evoke System regulatory legitimacy and clinical credibility, supporting adoption by providers and reimbursement discussions. Ongoing biomarker research for ADHD subtypes creates durable product differentiation and supports longer-term clinical utility and sales adoption.
Negative Factors
High operating cash burn
Sustained negative operating and free cash flow at multi-million dollar levels will deplete reserves unless revenue scales quickly or expense structure tightens. High cash burn forces reliance on external capital, constraining strategic choices and increasing dilution risk over subsequent quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
FDA-cleared Evoke platform
FDA 510(k) clearance gives the Evoke System regulatory legitimacy and clinical credibility, supporting adoption by providers and reimbursement discussions. Ongoing biomarker research for ADHD subtypes creates durable product differentiation and supports longer-term clinical utility and sales adoption.
Read all positive factors
Firefly Neuroscience (AIFF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$28.25M
Dividend YieldN/A
Average Volume (3M)316.76K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue Growth-86.22%
EPS Growth24.44%
CountryUS
Employees13
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-2.64
Shares Outstanding14,793,075
10 Day Avg. Volume358,037
30 Day Avg. Volume316,761
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.51
Price to Sales (P/S)10.11
P/FCF Ratio-1.39
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue19.62
Enterprise Value/Gross Profit34.73
Enterprise Value/Ebitda-1.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Firefly Neuroscience Business Overview & Revenue Model
Company Description
Firefly Neuroscience, Inc., a medical technology and artificial intelligence company, provides neuroscientific solutions that improve outcomes for patients with mental illnesses and neurological disorders. The company offers Brain Network Analytic...
How the Company Makes Money
null...
Firefly Neuroscience Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.14M | 108.00K | 498.00K | 0.00 | 32.00K |
| Gross Profit | 645.00K | 41.00K | 498.00K | 0.00 | 32.00K |
| EBITDA | -19.55M | -10.32M | -2.58M | -3.20M | -3.82M |
| Net Income | -19.88M | -10.46M | -2.60M | -3.79M | -4.38M |
Balance Sheet | |||||
| Total Assets | 10.48M | 4.60M | 2.64M | 135.00K | 953.00K |
| Cash, Cash Equivalents and Short-Term Investments | 2.75M | 1.81M | 2.14M | 58.00K | 653.00K |
| Total Debt | 0.00 | 694.00K | 0.00 | 0.00 | 1.79M |
| Total Liabilities | 2.84M | 4.98M | 2.53M | 2.25M | 3.97M |
| Stockholders Equity | 7.64M | -375.00K | 109.00K | -2.11M | -3.01M |
Cash Flow | |||||
| Free Cash Flow | -8.32M | -6.57M | -2.56M | -2.89M | -3.82M |
| Operating Cash Flow | -8.19M | -6.16M | -2.17M | -2.89M | -3.82M |
| Investing Cash Flow | -2.49M | -477.00K | -386.00K | 262.00K | 1.60M |
| Financing Cash Flow | 11.62M | 6.30M | 4.64M | 2.04M | 2.04M |
Firefly Neuroscience Technical Analysis
Negative
1.05
Price Trends
1.37
Positive
1.36
Positive
2.02
Negative
Market Momentum
0.20
Positive
50.87
Neutral
26.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIFF, the sentiment is Negative. The current price of 1.05 is below the 20-day moving average (MA) of 2.10, below the 50-day MA of 1.37, and below the 200-day MA of 2.02, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 50.87 is Neutral, neither overbought nor oversold. The STOCH value of 26.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIFF.
Firefly Neuroscience Risk Analysis
Firefly Neuroscience disclosed 60 risk factors in its most recent earnings report. Firefly Neuroscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Firefly Neuroscience Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
53 Neutral | $28.25M | -0.58 | -229.99% | ― | -86.22% | 24.44% | |
51 Neutral | $3.83B | ― | -38.33% | ― | 25.45% | 66.62% | |
50 Neutral | $73.04M | -8.98 | -109.73% | ― | ― | 50.39% | |
46 Neutral | $42.06M | -6.63 | -91.34% | ― | 250.35% | 83.06% |
* Technology Sector Average
AIFF
Firefly Neuroscience
1.91
-1.19
-38.39%
IRTC
Irhythm Technologies
118.63
15.18
14.67%
NMTC
NeuroOne Medical Technologies
0.83
0.40
92.79%
CGTX
Cognition Therapeutics
0.82
0.49
147.58%
Firefly Neuroscience Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Firefly Neuroscience Completes Private Placement and Lock-Up Agreements
Positive
Mar 12, 2026
On March 8, 2026, Firefly Neuroscience, Inc. entered into a securities purchase agreement with accredited investors to sell up to 13.5 million units at $1.50 per unit, combining common stock or pre-funded warrants with additional warrants at highe...
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and Financing
Firefly Neuroscience Launches ATM Equity Program to Fund Growth
Positive
Feb 4, 2026
On February 3, 2026, Firefly Neuroscience launched a $7.43 million at-the-market equity program with Konik Capital Partners to bolster working capital, offering flexibility to issue shares on Nasdaq while paying a 2% commission and standard indemn...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.